Sucampo Pharmaceuticals, Inc. (SCMP) – Financial and Strategic SWOT Analysis Review

Sucampo Pharmaceuticals, Inc. (SCMP) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $300

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
54
Pharmaceuticals and Healthcare
United States

Sucampo Pharmaceuticals, Inc. (SCMP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sucampo Pharmaceuticals, Inc. (Sucampo) is a biopharmaceutical company. The company conducts research, discovers, develops and commercializes proprietary drugs to address unmet medical needs. Its drugs are indicated for the treatment of gastrointestinal, ophthalmic, and cancer-based inflammatory disorders. Its marketed products include Amitiza, which is indicated for the treatment of chronic idiopathic constipation in adults, irritable bowel syndrome with constipation, opioid-induced constipation (OIC) in patients with chronic non-cancer pain and chronic constipation. Other prostone-based product candidates under development include lubiprostone and cobiprostone. The company, through its subsidiaries, operates in the UK, the US, Japan, and Switzerland. Sucampo is headquartered in Bethesda, Maryland, the US.

The company intends to maximize its market share, focus on clinical development activities, and enhance its scientific expertise.

Sucampo Pharmaceuticals, Inc. Key Recent Developments

Mar 04, 2015: Sucampo Reports Fourth Quarter and Full Year 2014 Financial Results and Corporate Update
Jan 30, 2015: Sucampo Appoints Andrew Smith, FCMA, CGMA as CFO
Jan 21, 2015: Robert J. Spiegel, M.D., FACP Joins Sucampo’s Board of Directors
Nov 06, 2013: Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2013 Credit Suisse Healthcare Conference
Nov 05, 2013: Sucampo Pharmaceuticals Reports Third Quarter and Nine Months 2013 Financial and Operating Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Sucampo Pharmaceuticals, Inc. – Key Facts 6
Sucampo Pharmaceuticals, Inc. – Key Employees 7
Sucampo Pharmaceuticals, Inc. – Key Employee Biographies 8
Sucampo Pharmaceuticals, Inc. – Major Products and Services 9
Sucampo Pharmaceuticals, Inc. – Pharmaceutical Pipeline Products Data 10
Sucampo Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Sucampo Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Sucampo Pharmaceuticals, Inc. – History 13
Sucampo Pharmaceuticals, Inc. – Company Statement 15
Sucampo Pharmaceuticals, Inc. – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Section 2 – Company Analysis 19
Sucampo Pharmaceuticals, Inc. – Business Description 19
Sucampo Pharmaceuticals, Inc. – Corporate Strategy 20
Sucampo Pharmaceuticals, Inc. – SWOT Analysis 21
SWOT Analysis – Overview 21
Sucampo Pharmaceuticals, Inc. – Strengths 21
Strength – Improved Financial Performance 21
Strength – Research and Development 21
Strength – Proprietary Prostone Technology 21
Sucampo Pharmaceuticals, Inc. – Weaknesses 22
Weakness – Unsuccessful Clinical Trials – Unoprostone Isopropyl 22
Weakness – Competitive Positioning 22
Sucampo Pharmaceuticals, Inc. – Opportunities 23
Opportunity – Strategic Alliances and Agreements 23
Opportunity – Robust Pipeline of Products 23
Opportunity – Oral Mucositis and Irritable Bowel Syndrome 23
Sucampo Pharmaceuticals, Inc. – Threats 24
Threat – Competitive Environment 24
Threat – Intellectual Property Risk 24
Threat – Dependence on Third Parties 24
Sucampo Pharmaceuticals, Inc. – Key Competitors 25
Section 3 – Company Financial Ratios 26
Financial Ratios – Capital Market Ratios 26
Financial Ratios – Annual Ratios 27
Performance Chart 29
Financial Performance 29
Financial Ratios – Interim Ratios 30
Financial Ratios – Ratio Charts 31
Section 4 – Company’s Lifesciences Financial Deals and Alliances 32
Sucampo Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 32
Sucampo Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 33
Sucampo Pharmaceuticals, Inc., Recent Deals Summary 34
Section 5 – Company’s Recent Developments 35
Mar 04, 2015: Sucampo Reports Fourth Quarter and Full Year 2014 Financial Results and Corporate Update 35
Jan 30, 2015: Sucampo Appoints Andrew Smith, FCMA, CGMA as CFO 38
Jan 21, 2015: Robert J. Spiegel, M.D., FACP Joins Sucampo’s Board of Directors 39
Dec 15, 2014: Sucampo Appoints John H. Johnson to Board of Directors 40
Nov 06, 2014: Sucampo Announces Third Quarter 2014 Financial Results 41
Oct 23, 2014: Sucampo Solidifies Leadership Team With Additions of CSO and Heads of Business Development, Regulatory Affairs 44
Oct 06, 2014: Sucampo Announces Departure of Chief Financial Officer 45
Aug 05, 2014: Sucampo Reports Second Quarter 2014 Financial Results and Corporate Update 46
Jul 22, 2014: Sucampo Pharmaceuticals Announces Second Quarter 2014 Financial Results and Corporate Update Teleconference and Webcast on August 5 48
Jul 22, 2014: Sucampo Pharmaceuticals Announces Second Quarter 2014 Financial Results 49
Section 6 – Appendix 50
Methodology 50
Ratio Definitions 50
About GlobalData 54
Contact Us 54
Disclaimer 54



List of Tables
Sucampo Pharmaceuticals, Inc., Key Facts 6
Sucampo Pharmaceuticals, Inc., Key Employees 7
Sucampo Pharmaceuticals, Inc., Key Employee Biographies 8
Sucampo Pharmaceuticals, Inc., Major Products and Services 9
Sucampo Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 10
Sucampo Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 11
Sucampo Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 12
Sucampo Pharmaceuticals, Inc., History 13
Sucampo Pharmaceuticals, Inc., Subsidiaries 18
Sucampo Pharmaceuticals, Inc., Key Competitors 25
Sucampo Pharmaceuticals, Inc., Ratios based on current share price 26
Sucampo Pharmaceuticals, Inc., Annual Ratios 27
Sucampo Pharmaceuticals, Inc., Interim Ratios 30
Sucampo Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 32
Sucampo Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 33
Sucampo Pharmaceuticals, Inc., Recent Deals Summary 34
Currency Codes 50
Capital Market Ratios 50
Equity Ratios 51
Profitability Ratios 51
Cost Ratios 52
Liquidity Ratios 52
Leverage Ratios 53
Efficiency Ratios 53



List of Figures
Sucampo Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Sucampo Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Sucampo Pharmaceuticals, Inc., Performance Chart (2010 – 2014) 29
Sucampo Pharmaceuticals, Inc., Ratio Charts 31
Sucampo Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 32
Sucampo Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 33

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $300

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.